MAM
AUPH icon

Martingale Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Martingale Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,252
Closed -$98.5K – 786
2025
Q1 		$98.5K Buy
+12,252
New +$99.3K ﹤0.01% 760

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Martingale Asset Management's AUPH Position: Q2 2025 in Review

Martingale Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2025, closing a stake of 12,252 shares — an estimated $98.5K sold.

Martingale Asset Management first reported a position in AUPH in Q1 2025 and held it in 1 quarter. The position peaked at $98.5K in Q1 2025. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

  • Martingale Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Martingale Asset Management sold 12,252 Aurinia Pharmaceuticals shares in Q2 2025, an estimated $98.5K.
  • Martingale Asset Management first reported a position in Aurinia Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Martingale Asset Management's Aurinia Pharmaceuticals position peaked at $98.5K in Q1 2025.
  • 219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Martingale Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.